Impact Biomedical, Inc. Announces U.S. Patent Allowance of Laetose™ Technology Entitled "Low Glycemic Sugar Composition." NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Impact Biomedical Inc. (IBIO), in which DSS Inc.(NYSE American: DSS) has a significant investment, is thrilled to announce a milestone in its innovative...

DSS, Inc. Chairman Chan Acquires 672,173 shares of DSS In Open Market NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS, “Company”), a multinational company operating across four distinct market sectors, announced today a significant investment...

DSS Inc. Receives Notice of Non-Compliance with NYSE American Trading Share Price Listing Rule NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- DSS, Inc.(NYSE American: DSS) announced today that the Company received a letter (the “Letter”) from the staff of NYSE American LLC (the “Exchange”)...

DSS, Inc. Announces Filing of Registration Statement on Form S-1 for Initial Public Offering of Impact Biomedical NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- DSS, Inc.(NYSE American: DSS) ("DSS") announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange...

DSS Inc. Expands DSS Wealth Management, Inc.'s Management Team for Ramp Up of Asset Management Subsidiary ROCHESTER, N.Y., Sept. 06, 2023 (GLOBE NEWSWIRE) -- DSS Wealth Management, Inc., a wholly owned subsidiary of DSS, Inc. and advisor to DSS AmericaFirst Quantitative Funds, is pleased to announce...